A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

Trial Details

NCT ID
NCT07174583
Phase
PHASE1 / PHASE2
Sponsor
IDEAYA Biosciences
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • IDE849
  • durvalumab
  • IDE161
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Orlando, Florida, United States|28.53834,-81.37924
  • Fort Wayne, Indiana, United States|41.1306,-85.12886
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Grand Rapids, Michigan, United States|42.96336,-85.66809

Key Eligibility Criteria

  • Are willing to participate in this clinical study, understand the study procedures, and are able to sign the written ICF.
  • Subjects with histologically or cytologically confirmed ES- SCLC, neuroendocrine carcinoma (NEC), DLL3+ solid tumors, are eligible per protocol. Su…
  • For SCLC, this includes platinum-based therapy and programmed death-1/programmed death-ligand 1 inhibitors (except for subjects who refuse, or are …
  • Subjects with NEC, this includes

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →